Spyglass Pharma (NASDAQ:SGP) Now Covered by Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Spyglass Pharma (NASDAQ:SGP) in a report released on Tuesday morning, MarketBeat.com reports. The firm issued a buy rating and a $42.00 target price on the stock.

A number of other equities analysts have also commented on SGP. Jefferies Financial Group began coverage on shares of Spyglass Pharma in a research report on Tuesday. They issued a “buy” rating and a $62.00 price target on the stock. Leerink Partners downgraded Spyglass Pharma to a “market perform” rating in a report on Tuesday. Finally, Wall Street Zen raised Spyglass Pharma to a “hold” rating in a report on Tuesday, February 17th. Four investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $47.00.

Spyglass Pharma Trading Up 0.1%

Shares of NASDAQ:SGP opened at $26.75 on Tuesday. Spyglass Pharma has a 52 week low of $20.16 and a 52 week high of $32.44.

Insider Buying and Selling at Spyglass Pharma

In related news, Director Ra Capital Management, L.P. purchased 3,690,000 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was acquired at an average price of $16.00 per share, with a total value of $59,040,000.00. Following the completion of the acquisition, the director directly owned 5,966,439 shares in the company, valued at approximately $95,463,024. This trade represents a 162.10% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

About Spyglass Pharma

We are a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation. Our lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), comprising novel, proprietary drug pads attached to our intraocular lens (IOL), is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients who have either open-angle glaucoma (OAG) or ocular hypertension (OHT).